Healthcare Industry News: Johnson and Johnson
News Release - March 5, 2007
AGA Medical Appoints Jack Darby as Vice President Worldwide Sales and Marketing
MINNEAPOLIS, March 5 (HSMN NewsFeed) -- AGA Medical Corporation ("AGA") today announced that it has appointed Jack Darby as Vice President Worldwide Sales and Marketing. He will report to John Barr, Chief Operating Officer, and will be based in AGA's Plymouth, Minnesota, corporate headquarters. In this newly created position, Jack will be responsible for all aspects of the global sales and marketing of AGA's products, including AGA's new U.S. sales force and all distributors outside of the U.S.Jack joins AGA from Cordis®, a Johnson and Johnson Company, where he served as Vice President of Global Stent Marketing. His primary responsibilities included all facets of global marketing and portfolio oversight for every Cordis® stent product, including the leading worldwide drug eluting stent, CYPHER®. During his tenure with Cordis® over the past 12 years, Jack has held a series of assignments with increasing responsibilities in business development and product commercialization, including executive sales management, commercial operations, customer inventory management, new business development, and product management. He also has extensive international experience, most notably a three year assignment in Tokyo as Director of Marketing for Cordis® Cardiology.
"We are pleased to have Jack Darby join the management team of AGA Medical," said Franck Gougeon, President and CEO of AGA. "Jack brings excellent experience in the cardiac cath lab and strong relationships with industry leaders. His experience in sales and marketing will be critical in building the strongest channels possible for AGA products worldwide. It says much about the opportunities ahead for AGA when we can attract an individual with Jack's record of accomplishment."
Jack holds a BS from the University of Michigan and served as a Captain in the Marine Corps.
ABOUT AGA MEDICAL: AGA Medical Corporation, based in Plymouth, Minnesota (just outside Minneapolis), is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the company has developed and commercialized a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart," such as atrial septal and patent foramen ovale defects. The company is expanding into new areas, including the minimally invasive repair of vascular abnormalities. Over 500 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices, such as improved patient outcomes, reduced length of stay and accelerated recovery times for the patient. AGA Medical devices have received regulatory approval and are marketed in over 90 countries with over 200,000 devices shipped to date. For more information visit http://www.amplatzer.com
Source: AGA Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
